EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis

Jonggi Choi, Daniel Fulop, Vy H Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G Simon, Raymond T Chung

Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 305-317

DOI: 10.3350/cmh.2025.0825 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von Jonggi Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Liver Cirrhosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing cause of cirrhosis and its complications. Given its close association with type 2 diabetes mellitus (T2DM), evaluating whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) can mitigate the progression of liver fibrosis is clinically important. We examined the association between SGLT2i use and liver fibrosis progression in patients diagnosed with MASLD and T2DM.

Methods

We conducted a target trial emulation study using a retrospective, active comparator new-user design among adults with MASLD, T2DM, and low-to-intermediate Fibrosis-4 (FIB-4≤2.67) scores who initiated treatment with either SGLT2is or dipeptidyl peptidase-4 inhibitors (DPP-4is) at Mass General Brigham or Asan Medical Center from 2013 to 2023. The primary outcome was the progression to advanced fibrosis (FIB-4>2.67), confirmed on ≥2 occasions within 1 year. The secondary outcome was the development of major adverse liver outcomes (MALO), including incident cirrhosis, decompensation events, hepatocellular carcinoma, or liver transplantation.

Results

Among 16,901 eligible patients, 2,571 propensity score-matched pairs were identified with balanced baseline characteristics. During follow-up (median, 3.7 years), fibrosis progression occurred at a rate of 3.46/100 personyears in SGLT2i users and 4.44 in DPP4i users. SGLT2i use was associated with a lower risk of fibrosis progression (HR 0.78, 95% CI 0.67–0.89; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsLiver CirrhosisFatty LiverHumansMaleFemaleMiddle AgedDisease ProgressionRetrospective StudiesAgedAdult

Stichwörter der Autor:innen

Fatty liverFibrosisLiver fibrosisMASLD

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Liver Center, Gastroenterology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Förderung

  • NIH HHS
  • NCI NIH HHS
  • Gilead Sciences
  • National Institutes of Health

Zitieren

APA

Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2026). Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. Clinical and Molecular Hepatology, 32(1), 305-317. https://doi.org/10.3350/cmh.2025.0825

Vancouver

Choi J, Fulop D, Nguyen VH, Przybyszewski E, Song J, Carroll A, et al. Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis. Clinical and Molecular Hepatology. 2026;32(1):305-317. doi:10.3350/cmh.2025.0825

BibTeX
@article{Choi2026,
  author = {Choi, Jonggi and Fulop, Daniel and Nguyen, Vy H and Przybyszewski, Eric and Song, Jiunn and Carroll, Allison and Michta, Megan and Almazan, Erik and Simon, Tracey G and Chung, Raymond T},
  title = {Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {305--317},
  doi = {10.3350/cmh.2025.0825}
}
Kostenlos starten →